Cyclo Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cyclo Therapeutics Inc (CYTH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cyclo Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 2,597M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+7.4% annualized vs trailing 12 months), vs decelerating (-7.8%) for its tracked peer group.
- Growth: Cyclo Therapeutics Inc generated -52.8% revenue growth year over year in Q4 2024, vs 39.1% for its competitors combined.
- Profitability: Its -3,778.4% net margin compares with -71.1% for the peer group.
- Peer revenue share: Cyclo Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.03M compares with $0.69M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CYTH Sales vs. its Competitors, Q4 2024
Cyclo Therapeutics Inc reported revenue contraction of 52.82 % year on year in Q4 2024, below its competitors' combined revenue growth of 39.06 %.
With a net margin of -3,778.44 %, Cyclo Therapeutics Inc reported lower profitability than its competitors (-71.05 %).
Cyclo Therapeutics Inc generated 0.04 % of the combined sales of its peer group, down from 0.11 % a year earlier.
API endpoints for this dataset
Cyclo Therapeutics Inc vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Cyclo Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cyclo Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cyclo Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cyclo Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.9% year over year, combined, vs -52.8% for Cyclo Therapeutics Inc. Cyclo Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Cyclo Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cyclo Therapeutics Inc | - | No | No | No |
| Competitors combined (21) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CYTH Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Boundless Bio Inc | 282.9% | Outperformed |
| 2 | Contextlogic Inc | 282.9% | Outperformed |
| 3 | Solid Biosciences Inc | 282.9% | Outperformed |
| 4 | Protalix Biotherapeutics inc | 282.9% | Outperformed |
| 5 | 4d Molecular Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cyclo Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cyclo Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Cyclo Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Cyclo Therapeutics Inc |
20.70 | 0.87 |
 Crispr Therapeutics Ag |
4,123.10 | 25.17 |
 Sarepta Therapeutics Inc |
1,695.94 | 1,956.34 |
 Taysha Gene Therapies Inc |
1,553.68 | 8.10 |
 Solid Biosciences Inc |
1,005.82 | 14.79 |
 4d Molecular Therapeutics Inc |
851.35 | 92.01 |
| SUBTOTAL | 11,948.43 | 2,677.50 |
Sign in to see all competitors of Cyclo Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cyclo Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cyclo Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Cyclo Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Orphazyme A | Company report | 85% |
Company report basis, confidence, active dates and source counts for Cyclo Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Cyclo Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
| Editas Medicine Inc | Reportable 100.00 % |
| Protalix Biotherapeutics inc | Single operating segment 100.00 % |
| Voyager Therapeutics Inc | Single reportable segment 100.00 % |
| Sangamo Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Cyclo Therapeutics Inc .
Cyclo Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cyclo Therapeutics Inc | 21 | 30,025 | -855,173 |
| Crispr Therapeutics Ag | 4,123 | 125,234 | -2,269,328 |
| Sarepta Therapeutics Inc | 1,696 | 2,342,921 | -137,267 |
| Taysha Gene Therapies Inc | 1,554 | 81,798 | -1,511,444 |
| Solid Biosciences Inc | 1,006 | 122,190 | -1,711,562 |
| 4d Molecular Therapeutics Inc | 851 | 469,429 | -914,158 |
| PEERS TOTAL | 11,928 | 691,100 | -648,892 |
Sign in to see all peers for Cyclo Therapeutics Inc .
Cyclo Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| 4d Molecular Therapeutics Inc | JP 97.83 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cyclo Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 93.40 % | 35.21 % (avg) | +58.2 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.12 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.28 % | 8.47 % (avg) | -8.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cyclo Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | -8.7x | 5.1x | -13.8x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -11.27 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cyclo Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 58.13 % | -17.64 % | 28.08 % | -36.47 % | -10.31 % | 75.54 % | -13.24 % | -21.76 % |
| Operating Margin | -279.85 % | -310.51 % | -269.14 % | -749.06 % | -991.99 % | - | - | - |
| Return on Invested Capital | -78.08 % | -117.11 % | -330.47 % | -176.17 % | -277.09 % | -107.28 % | -107.24 % | -2,179.67 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cyclo Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.28 % vs industry average 8.47 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Cyclo Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Cyclo Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+7.4% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (66.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-7.8% annualized).
Methodology: see Methodology: SWOT Analysis.
Cyclo Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cyclo Therapeutics Inc | 0.33 | 0.61 | - |
| Crispr Therapeutics Ag | 2.24 | 16.26 | 0.25 |
| Sarepta Therapeutics Inc | 0.84 | 3.39 | 0.62 |
| Taysha Gene Therapies Inc | 13.32 | 13.51 | 0.19 |
| Solid Biosciences Inc | 6.19 | 9.65 | - |
| 4d Molecular Therapeutics Inc | 1.46 | 8.79 | 0.01 |
Sign in to see all peers for Cyclo Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cyclo Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cyclo Therapeutics Inc | Q3 2024 | -52.8 % | - |
| Crispr Therapeutics Ag | Q3 2026 | +1,325.1 % | - |
| Sarepta Therapeutics Inc | Q3 2026 | -4.5 % | - |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
| Solid Biosciences Inc | Q2 2026 | - | - |
| 4d Molecular Therapeutics Inc | Q2 2026 | +25,106.7 % | - |
| PEERS TOTAL | +5.5 % | - |
Sign in to see all peers for Cyclo Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cyclo Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cyclo Therapeutics Inc | Q3 2024 | - | - |
| Crispr Therapeutics Ag | Q3 2026 | - | +459.5 % |
| Sarepta Therapeutics Inc | Q3 2026 | - | -78.3 % |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
| Solid Biosciences Inc | Q2 2026 | - | -60.2 % |
| 4d Molecular Therapeutics Inc | Q2 2026 | - | -16.7 % |
Sign in to see all peers for Cyclo Therapeutics Inc .
Cyclo Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cyclo Therapeutics Inc | - | - | - |
| Crispr Therapeutics Ag | - | - | - |
| Sarepta Therapeutics Inc | - | - | - |
| Taysha Gene Therapies Inc | - | - | - |
| Solid Biosciences Inc | - | - | - |
| 4d Molecular Therapeutics Inc | - | - | - |
Sign in to see all peers for Cyclo Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cyclo Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cyclo Therapeutics Inc | - | 23.78 |
| Crispr Therapeutics Ag | - | 163.80 |
| Sarepta Therapeutics Inc | - | 0.87 |
| Taysha Gene Therapies Inc | - | 191.86 |
| Solid Biosciences Inc | - | 68.03 |
| 4d Molecular Therapeutics Inc | - | 9.25 |
| PEERS AVERAGE | - | 4.46 |
Sign in to see all peers for Cyclo Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.